NCT06705192View on ClinicalTrials.gov

Study in Asymptomatic GRN-FTD Patients to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

August 5, 2025

Study Completion Date

August 5, 2025

Conditions
DementiaFrontotemporal DementiaAsymptomatic Condition
Interventions
DRUG

VES001

"VES001 is an oral, blood brain barrier ligand of sortilin.~VES001 will be administered orally as a solid within a gelatine capsule without excipients; the capsule strength will be 180 mg."

Trial Locations (2)

Unknown

Erasmus University Medical Center, Rotterdam

Leonard Wolfson Experimental Neurology Centre CRF National Hospital for Neurology and Neurosurgery, London

All Listed Sponsors
lead

Mads Kjolby

INDUSTRY

NCT06705192 - Study in Asymptomatic GRN-FTD Patients to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 | Biotech Hunter | Biotech Hunter